Guildford, United Kingdom
SiSaf Ltd, headquartered in the United Kingdom, is a pioneering company in RNA delivery and therapeutics. Founded in 2008, the company has carved a niche in the Biotechnology, Health Care, and Pharmaceutical industries with its innovative approach to addressing the limitations of existing RNA delivery technologies.
The company has developed its proprietary Bio-Courier® technology, which focuses on the hybridization of organic materials with inorganic bioabsorbable silicon, ultimately enhancing the stability and efficacy of RNA therapeutics. Their cutting-edge silicon stabilized hybrid lipid nanoparticles (sshLNP) are leading the charge in tackling rare genetic disorders through improved RNA transfection efficiency.
Under the leadership of founder and biomaterials expert Dr Suzanne Saffie-Siebert, SiSaf has attracted significant venture capital backing. Their most recent funding round, a $13.20M Series B investment in November 2020, was led by esteemed investors such as Vickers Venture Partners and Future Fund, enabling them to build a robust patent portfolio and scalable technological infrastructure.
